Travere Therapeutics (TVTX) Receivables - Other (2011 - 2026)

Travere Therapeutics (TVTX) has 10 years of Receivables - Other data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 42.86% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 42.86% YoY), and the FY2025 full-year result was $1.3 million, down 43.48% from the prior year.
• Receivables - Other for Q1 2026 stood at $1.2 million, down from $1.3 million in the prior quarter.
• Across five years, Receivables - Other topped out at $4.6 million in Q4 2023 and bottomed at $1.2 million in Q1 2026.
• The 5-year median for Receivables - Other is $2.2 million (2024), against an average of $2.4 million.
• The widest annual swing landed in 2023, when Receivables - Other soared 142.11%; it then tumbled 50.0% in 2024.
• A 5-year view of Receivables - Other shows it stood at $1.9 million in 2022, then jumped by 142.11% to $4.6 million in 2023, then sank by 50.0% to $2.3 million in 2024, then plunged by 43.48% to $1.3 million in 2025, then dropped by 7.69% to $1.2 million in 2026.
• The last three Receivables - Other figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.

Peer Comparison